Amgen Inc.'s investor-pleasing fourth quarter and full 2015 earnings won the customary nods from analysts, who promptly zeroed in on the next major milestone – phase III data in osteoporosis with romosozumab in postmenopausal women, and how those "romo" results might stack up against the bone drug abaloparatide from Radius Health Inc., which has already made a strong phase III showing against Forteo (teriparatide, Eli Lilly and Co.) in the trial called ACTIVE.